CAESAREA, Israel, Dec. 10, 2025 — Nitinotes Ltd., an early commercial-stage medical technology company developing fully automated endoluminal suturing solutions for obesity treatment, announced that the first patient has been treated in its U.S. Investigational Device Exemption (IDE) EASE™ Clinical Trial, a pivotal study evaluating the EndoZip™ Automated Suturing System for endoscopic sleeve gastroplasty (ESG). The milestone procedure was performed at Lenox Hill Hospital | Northwell Health in New York, marking the activation of the trial’s first U.S. site and advancing the company toward eventual FDA submission.
Science Significance
The initiation of the EASE™ trial marks a critical scientific advance in the evolution of ESG technology. The randomized, two-arm, blinded study directly compares the automated EndoZip™ ESG approach with the established manual Apollo OverStitch® technique, generating first-of-its-kind evidence on whether automation can deliver greater precision, reproducibility, procedural consistency, and workflow efficiency in obesity intervention. With obesity affecting more than 650 million individuals worldwide, understanding whether automated suturing can enhance the technical and biological outcomes of ESG is scientifically significant, potentially shaping future standards for minimally invasive bariatric alternatives.
Regulatory Significance
The pivotal IDE study is explicitly designed in alignment with FDA guidance, and its data will form the backbone of Nitinotes’ anticipated U.S. regulatory submission for EndoZip™. By enrolling up to 184 patients across up to 10 clinical sites in the U.S. and Europe with 12-month follow-up, the trial is structured to meet the regulatory expectations for safety, effectiveness, and usability evidence for a new ESG medical device. The first-patient milestone also follows the system’s recent CE Mark approval, demonstrating that EndoZip™ has already met stringent European Union regulatory requirements and providing global regulators with early confidence in its risk-benefit profile.
Business Significance
Advertisement
For Nitinotes, the launch of the EASE™ trial represents a major step in transitioning from early commercial stage to broader market expansion. The combination of CE Mark approval and the initiation of a pivotal U.S. IDE trial strategically positions the company for commercial scaling in Europe and regulatory progression in the United States, two key growth markets in obesity treatment technologies. As automated ESG systems may reduce operator variability and expand procedural accessibility, EndoZip™ could help broaden the ESG market footprint and strengthen Nitinotes’ competitive position in the rapidly growing MedTech obesity-treatment sector.
Patients’ Significance
For patients living with obesity—many of whom experience insufficient results with lifestyle or pharmacologic therapy and are reluctant to pursue invasive bariatric surgery—the development of automated ESG solutions offers the promise of a less invasive, standardized, and potentially more accessible treatment pathway. Automated suturing may provide consistent outcomes across operators and institutions, reducing dependency on highly specialized manual skills. With dropout rates from GLP-1 therapy remaining high, the availability of safe, minimally invasive options supported by rigorous clinical data could significantly expand meaningful treatment choices for patients seeking durable weight-loss solutions.
Policy Significance
The trial reflects global health policy trends that increasingly support innovation in metabolic disease treatment, minimally invasive technologies, and evidence-based obesity interventions. As healthcare systems face rising costs associated with obesity, technologies that improve procedural standardization and reduce reliance on technically demanding surgical skills align with policy priorities promoting equitable access and scalable care models. The study’s FDA-guided design further strengthens the alignment between MedTech innovation and regulatory policy, contributing to a future framework that enables automation-driven approaches to be evaluated and adopted safely and responsibly.
Nitinotes’ first-patient treatment in the pivotal EASE™ Clinical Trial marks a major advancement in automated ESG development and represents a decisive step toward U.S. market entry for the EndoZip™ system. Building on recent CE Mark approval, the company’s commitment to generating high-quality evidence underscores its strategic vision to transform obesity care with automation-driven solutions. As additional U.S. and European clinical sites initiate enrollment, the trial’s outcomes may play a central role in shaping the future of endoluminal suturing and expanding the therapeutic landscape for millions seeking effective, minimally invasive weight-loss options.
Source: Nitinotes press release
